Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hepatocellular carcinoma].

C Czauderna1, J U Marquardt1, P R Galle2

  • 1I. Medizinische Klinik und Poliklinik/Cirrhose Centrum Mainz (CCM), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland.

Der Internist
|April 8, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Innere Medizin (Heidelberg, Germany)·2026
Same author

Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma.

ESMO open·2025
Same author

Mitochondrial topoisomerase I (Top1MT) prevents the onset of metabolic dysfunction-associated steatohepatitis (MASH) in mice.

bioRxiv : the preprint server for biology·2024
Same author

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

[68/m-Massive rectal bleeding : Preparation for the medical specialist examination: part 148].

Der Internist·2022
Same author

[65/f-Fever and acute left lower quadrant abdominal pain : Preparation for the medical specialist examination: part 139].

Der Internist·2022
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
See all related articles

Hepatocellular carcinoma (HCC), a malignant liver cancer, is a leading cause of death in cirrhosis patients. Early detection and personalized medicine are crucial due to rising incidence and treatment challenges.

Area of Science:

  • Hepatology and Oncology
  • Gastroenterology
  • Cancer Research

Background:

  • Hepatocellular carcinoma (HCC) is a prevalent and aggressive malignancy, frequently arising in patients with liver cirrhosis.
  • Liver cirrhosis is the primary risk factor for HCC development.
  • Rising rates of nonalcoholic steatohepatitis predict an increase in HCC incidence in Western nations.

Purpose of the Study:

  • To highlight the critical need for early identification and surveillance of patients at risk for hepatocellular carcinoma.
  • To underscore the challenges in treating HCC due to underlying liver cirrhosis, necessitating multimodal and interdisciplinary approaches.
  • To emphasize the requirement for personalized precision medicine in HCC management owing to its heterogeneity.

Main Methods:

Keywords:
Chemoembolization, therapeuticEarly detection of cancerLiver cirrhosisLiver transplantationPersonalized medicine

Related Experiment Videos

  • Review of current literature on HCC epidemiology and risk factors.
  • Analysis of therapeutic strategies and challenges in managing HCC in cirrhotic patients.
  • Discussion of the impact of tumor heterogeneity on treatment development.

    • Main Results:

    • Early-stage HCC offers the only window for curative treatments.
    • Therapeutic options for HCC are constrained by the presence of liver cirrhosis.
    • Significant morphological and genetic heterogeneity complicates the development of effective HCC treatments.

    Conclusions:

    • Effective management of hepatocellular carcinoma requires early detection and risk stratification.
    • Multimodal and interdisciplinary approaches are essential for treating HCC in cirrhotic patients.
    • Personalized precision medicine is imperative to overcome HCC heterogeneity and improve patient outcomes.